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It is well known that lesions morphologically identical with
focal segmental glomerulosclerosis (FSGS) may appear in IgA
nephropathy (IgAN). Capsular adhesions without underlying
abnormalities in the tuft, often the first sign of FSGS, are
frequent in IgAN. In this retrospective study, a new cohort of
128 adult patients with IgAN was used to validate the new
Oxford classification system of IgAN, and shown to have
highly significant associations with clinical and outcome
parameters. We then used these patients to determine the
extent to which IgAN could be accounted for in terms of
FSGS. Some form of lesion consistent with FSGS, notably
hyalinosis and collapsing glomerulopathy, was found in
101 of these patients. No glomerular lesions were found in
16 patients, and 11 had mild lesions not definable as FSGS.
Those with FSGS had significantly worse renal survival at
80 months than those without. Comparison of pure forms of
FSGS (excluding collapsing glomerulopathy) with cases of
FSGS having other glomerular lesions (mesangial
hyperplasia, endocapillary hypercellularity, glomerular
necroses, extracapillary proliferation) revealed that those
with FSGS and other superimposed lesions did significantly
worse than cases of pure FSGS at 80 months following
diagnosis. Importantly, patients with pure FSGS had relatively
poor survival even without other superimposed glomerular
abnormalities. Thus, the majority of cases of IgAN can be
interpreted as representing one or another variant of FSGS.
Hence, interpreting IgAN in terms of FSGS emphasizes the
role that podocyte lesions may play in the pathogenesis and
progression of this disease.
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From the time of its first description,1,2 IgA nephropathy
(IgAN) has been considered to be an immune complex
disease, whose immunoglobulin moiety is now known
to represent, in large part, mesangial and capillary wall
deposits of an abnormal IgA1 with defects in its hinge
region.3–5 Much effort has been directed toward elucidating
the mechanisms of interaction of the complexes with
mesangial cells and the mechanisms of complement
activation leading to mesangial and intracapillary prolifera-
tive lesions.6–8 Our thinking has been molded in no
small part by the often-striking resemblance of IgAN to the
lesions of lupus nephritis, a prototypical immune complex
disease.
However, it has long been known that lesions morpho-
logically identical with focal segmental glomerulosclerosis
(FSGS) may appear in IgAN,3,9–13 and FSGS was included as a
separate class in an earlier classification of IgAN.10 FSGS is a
histological pattern resulting from a variety of mechanisms,
hereditary, infectious, toxic, and adaptive responses to
reduced functioning renal mass.14 All have in common
damage to and/or loss of podocytes, thus qualifying as
podocytopathies.
Several considerations prompted us to explore further, in
a series of 128 patients, the question as to the extent to which
the glomerular lesions in IgAN might be considered as
representing the results of FSGS. First, in addition to the
studies cited above, we found in preliminary analysis of our
cases that nearly half had typical FSGS with hyalinosis or
collapsing glomerulopathy. We were also struck, as others
have been,15–17 by the high frequency of glomerular capsular
adhesions in IgAN, often accompanied by evident epithelial
changes. Such adhesions are extremely common in FSGS, and
Kriz18,19 has referred to them as the ‘first committed step’ in
FSGS. Finally, there is evidence for podocyte loss in IgAN,
first in terms of the number of podocytes/glomerulus,20 and
second urinary loss of podocytes,21 both of which correlate
with disease progression. We indeed found that the majority
of cases of IgAN can be interpreted as representing one or
another of the variants of FSGS. This observation suggests
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that the immune complexes of IgAN must be acting in a
significant part on the podocytes, and evidence is beginning
to accumulate as to the mechanisms by which IgA1 may exert
its effects on podocytes.22–27
RESULTS
A total of 128 (87 males, 70.7%) were included in this
retrospective study. There were 118 (92.2%) Caucasians, 10
(7.8%) Asians, and no blacks. Mean age was 38.7 years (range
18–78). Mean proteinuria was 2.43 g/day (s.e.m. 0.25), with
only 6 patients presenting with no measurable proteinuria,
and 97 patients (73.1%) having proteinuria 40.5 g/day.
Renal insufficiency was frequent, with 73 patients (57%)
presenting with serum creatinine (SCr)4120mmol/l, of whom
35 had SCr 4200mmol/l. Mean glomerular filtration rate
(GFR) was 52.1ml/min per 1.73m2 (s.e.m. 2.9). All the patients
except one (who was pregnant) received angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonists, or both
for hypertension and/or persistent proteinuria. Only one
patient had received corticosteroid therapy during the 6
months before diagnosis, and none had steroid therapy
subsequent to diagnosis. No patient had other immunosup-
pressive therapy, either before or subsequent to diagnosis.
Morphologic lesions and clinical correlations
Morphologic lesions will be discussed first in terms of the
new Oxford classification15,16 and of immunofluorescence
results. Following this, they will be described in terms of their
interpretation as lesions of FSGS.
Oxford classification
The four Oxford criteria15,16 (Table 1) were analyzed in our
material and all were found to correlate extremely well with
clinical and outcome parameters (Table 2). Several comments
about each should be made.
Mesangial hypercellularity. Using the criterion of X4
nuclei/glomerular lobule as indicative of hypercellularity,
we found 42 patients with mesangial hypercellularity in
450% of glomeruli (Figure 1a). However, mesangial
hypercellularity occurred almost exclusively in the context
of lesions interpretable as FSGS (40/42 cases), particularly
FSGS with hyalinosis (22 cases).
Segmental glomerulosclerosis. Segmental glomerulo-
sclerosis as used in the Oxford classification includes all
segmental scars, including capsular adhesions in this
category. The term should not be taken as synonymous with
FSGS, for it also includes scars of indeterminate origin (see
below and Figure 2). It occurred to some degree in 91
(72.8%) patients, a percentage similar to that in the Oxford
study (76%; Figure 1b).
Endocapillary lesions. Endocapillary lesions with obstruc-
tion of capillary lumens by infiltrating cells, generally focal in
distribution, were found in 31 patients (24.7%; Figure 1c).
Once again, 29/31 examples occurred in a context interpretable
Table 1 | Definitions of Oxford criteria for IgA nephropathy and of the Columbia classification of FSGS as applied to IgA
nephropathy
Oxford criteria for IgA nephropathy
Term Definition
Mesangial hypercellularity 44 to 5 mesangial cells/mesangial area in 450% of glomeruli
Segmental
glomerulosclerosis
Any amount of the tuft involved in sclerosis, but not involving the entire tuft or the presence of an adhesion,
in X1 more glomeruli
Endocapillary
hypercellularity
Hypercellularity due to increased number of cells within glomerular capillary lumina causing narrowing of
the lumina, segmental or diffuse in at least one glomerulus, graded as present/absent from biopsy
Tubular atrophy/
Interstitial fibrosis
Percentage of cortical area involved by tubular atrophy or interstitial fibrosis, whichever is greater
T0, 0–25%; T1, 26–50%; T2, 450%a
Columbia classification of FSGS in the context of IgA nephropathy
Variant Inclusion criteria Exclusion criteria
FSGS, NOS At least 1 glomerulus with segmental increase in matrix obliterating the capillary lumina,
or segmental glomerular capillary collapse, associated with hyalinosis lesions and/or
epithelial hypertrophy/hyperplasiab
Exclude perihilar, cellular, tip,
and collapsing variants
Perihilar variant At least one glomerulus with perihilar hyalinosis, with or without sclerosis. 450% of
glomeruli with segmental lesions must have perihilar sclerosis and/or hyalinosis
Exclude cellular, tip, and
collapsing variants
Cellular variant At least one glomerulus with segmental endocapillary hypercellularity occluding lumina,
with or without foam cells and karyorrhexis, with hyperplasia of overlying epitheliumc
Exclude tip and collapsing
variants
Tip variant At least one segmental lesion involving the tip domain (outer 25% of tuft next to origin of
proximal tubule). The tubular pole must be identified in the defining lesion. The lesion
must have either an adhesion or confluence of podocytes with parietal or tubular cells
at the tubular lumen or neck. Tip lesion may be cellular or sclerosing
Exclude collapsing variant
and any perihilar sclerosis
Collapsing variant At least 1 glomerulus with segmental or global collapse and overlying podocyte
hypertrophy and hyperplasia
None
Abbreviations: FSGS, focal segmental glomerulosclerosis; NOS, not otherwise specified.
aT-grades used only in Table 1. In other analyses, the actual percentages of tubular atrophy/interstial fibrosis are used.
bAdded to exclude segmental scars of possible non-FSGS origin.
cAdded to exclude endocapillary hypercellularity of possible non-FSGS origin.
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as FSGS. Differences in clinical and outcome parameters,
although significant, were not as impressive as for the other
Oxford criteria (Table 2).
Tubular atrophy/interstitial fibrosis. It was evident here
that our cases were more advanced than those in the Oxford
study15,16 (Figure 1d). Although roughly 10% of cases in each
study showed no significant fibrosis, B48% of cases in the
Oxford study showed interstitial fibrosis graded at p10
versus 22% in this study. As might be expected, this criterion
translated into the most highly significant difference for
clinical and outcome parameters of any of the parameters
(Table 2).
Other lesions. Glomerular necroses were present in 9
patients (8.5%), compared with 2.2% in the Oxford study
(Figure 2a). Interestingly, they had no pejorative effect on
outcome with none having a bad outcome.
Extracapillary proliferation occurred in 31 (24.2%) of our
cases, a lower percentage than in the Oxford study (45%), but
as in that study generally only involving a limited number of
glomeruli. All of these occurred in cases interpretable as
FSGS, including the cellular variant of FSGS (12 cases) and
collapsing glomerulopathy (8 cases), and in that context the
majority would be regarded as representing pseudocrescents
(see below). There was no difference in the frequency of
glomerular necroses between those with extracapillary
proliferation (2/31¼ 6.5%) and those without (7/97¼
7.2%). Cases with extracapillary proliferation had more
severe morphologic, clinical, and outcome parameters than
those without, with 46.7 versus 23.9% finishing on dialysis
(P¼ 0.05).
Immunofluorescence results
All cases in our series showed glomerular positivity for IgA as
the predominant immunoglobulin. Deposits were predomi-
nantly mesangial, with some cases showing subendothelial
deposits and occasionally subepithelial deposits, as in most
series.3 However, one aspect that has been little commented
upon was the presence in a number of cases of IgA-positive
droplets positive in podocytes and parietal epithelial cells
(PECs), often to the exclusion of other immunoglobulins
(Figure 1e and Supplementary Figure S3 online). These
droplets appear to correspond to the bright red ‘resorption’
droplets seen on light microscopy in many cases (Figure 1f
and Supplementary Figure S4 online).
Lesions considered in terms of FSGS
Definition of diagnostic criteria for FSGS in the context of
IgAN. We wished to apply the Columbia 2004 classification
of FSGS14 as nearly as possible to our cases of IgAN. For
collapsing glomerulopathy, the tip, and perihilar variants of
Table 2 | Evaluation of variables of Oxford classification in terms of clinical parameters
Mesangial hypercellularity Segmental glomerulosclerosis
Present Absent P-value Present Absent P-value
42 patients 82 patients 105 patients 47 patients
Systolic BPdx 150 (135–170) 133 (120–150) 0.0004 144 (129–164) 125 (120–137) 0.006
Diastolic BPdx 90 (80–102) 80 (70–93) 0.007 84 (70–100) 80 (70–89) NS
Malignant HTN 11/42=26.1% 8/82=6.1% 0.017 15/105=15.2% 1/20=5.0% NS
SCrdx 219 (156–450) 108 (90–167) 0.000001 160 (106–248) 106 (91–161) 0.00006
GFRdx 31.3 (13.1–43.3) 62.1 (40.9–84) 0.000001 43 (26–66) 66.3 (44–84.6) 0.0003
Proteinuriadx 2.9 (2.0–5.5) 1.0 (0.5–2.4) 0.000001 2.0 (0.9–3.3) 0.4 (0.1–1.1) 0.00003
SCrend 219 (156–450) 111 (90–176) 0.0001 149 (107–279) 97 (83–105) 0.0008
GFRend 0 (0–32.6) 55 (30–81) 0.000001 34 (0–61) 75.1 (55.0–100.3) 0.00003
Bad outcomea 25/41=61.0% 15/79=19.0% 0.0000 40/99=40.4% 1/19=5.3% 0.0012
Dialysis 21/39=53.8% 13/78=16.7% 0.0000 34/99=34.3% 1/19=5.3% 0.0051
Endocapillary proliferation Tubular atrophy/interstitial fibrosis
Present Absent P-value T2 (450%) T0 (o25%)
31 patients 95 patients 29 patients 66 patients
Systolic BPdx 144 (130–170) 136 (121–180) NS 170 (152–2010) 130 (120–148) 0.000000
Diastolic BPdx 83 (70–102) 84 (70–97) NS 104 (90–120) 80 (70–88) 0.000002
Malignant HTN 8/31=25.8% 9/95=9.5% NSb 14/29=44.8% 0/46=0% 0.0000
SCrdx 198 (145–1710) 124 (91–195) 0.001 450 (236–823) 100 (81–126) 0.000000
GFRdx 34.4 (13.1–48.5) 54.3 (34.1–82.7) 0.0008 12.9 (5.7–27.9) 72.6 (53.6–90.0) 0.000000
Proteinuriadx 3.0 (2.3–5.1) 1.2 (0.6–2.4) 0.000004 3.0 (2.1–4.8) 1.0 (0.4–1.7) 0.000002
SCrend 210 (133–533) 115 (90–196) 0.003 480 (197–751) 107 (88–118) 0.000005
GFRend 14.1 (0.0–35.8) 51.5 (7.6–75.1) 0.0005 0.0 (0.0–24.4) 66.8 (51.1–88.4) 0.000000
Bad outcomea 15/29=51.7% 24/89=27.0% NSb 21/29=72.4% 3/64=4.7% 0.0000
Dialysis 13/29=44.8% 22/89=24.7% NSb 19/28=67.9% 2/64=3.1% 0.0000
Abbreviations: BP, blood pressure; dx, diagnosis; GFR, glomerular filtration rate; HTN, hypertension; NS, not significant; SCr, serum creatinine.
Values expressed as median (25–75th quartiles) or as percentages. Probabilities calculated using Mann–Whitney U-test or Fisher’s exact test, as appropriate.
aBad outcome defined as doubling of SCr or need for dialysis.
bAs corrected by Holm–Bonferroni method to minimize type 1 statistical error (a=0.05).
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FSGS, it was possible to apply the Columbia criteria directly.
However, in the instance of the FSGS not otherwise
specified (NOS), we were forced to use more stringent
criteria. In primary FSGS,14 the NOS category was defined as
a ‘segmental increase in matrix obliterating capillary lumina,
also segmental collapse without overlying podocyte
IgA
Figure 1 | Lesions of FSGS in IgA nephropathy. (a) Oxford criterion—mesangial hypercellularity. Multiple lobules show mesangial
hypercellularity with 44 cells/lobule. Note also capsular adhesions (arrows) and reactive epithelial cells (right). Masson trichrome (MT),
original magnification  400. (b) Oxford criterion—segmental glomerulosclerosis. In this instance, several hyalinosis lesions in nonhilar
positions are seen. MT, original magnification  450. (c) Oxford criterion—endocapillary hypercellularity. Several lobules show marked
endocapillary hypercellularity with occlusion of capillary lumens. The hyperplastic epithelial cells and the zone of lighter staining collagen
(arrow) are consistent with the cellular variant of focal segmental glomerulosclerosis (FSGS). MT, original magnification  350. (d) Oxford
criterion—tubular atrophy/interstitial fibrosis. Advanced tubular atrophy and interstitial fibrosis. In this field they surround a glomerulus
showing collapsing glomerulopathy, with numerous tubules showing vacuolated macrophagic cells. MT, original magnification  250.
(e) Immunofluorescence for IgA. Diffuse mesangial staining with small clusters of droplets (arrows) in epithelium adjacent to Bowman’s
capsule. original magnification  600. (f) Hyaline droplets in epithelium, adjacent to segmental scar. Droplets (arrow) are predominantly in
cells identifiable as parietal epithelial cells (PECs) but also in cells overlying tuft. MT, original magnification  850. (g) Parietal epithelial cells
at adhesion. Here growing along an adhesion (not in this plane of section) onto the glomerular tuft. Light-staining matrix (arrow) suggests
that the adherent lesion was a form of FSGS. MT, original magnification  450. (h) Cellular variant of FSGS. Note continuity of PECs
from capsule onto glomerular tuft. Elsewhere, the epithelium is tall and vacuolated; such epithelium stains as being of PEC origin
immunohistochemically. MT, original magnification  350. (i) Collapsing glomerulopathy. The collapsed capillary loops are covered with a
layer of hyperplastic epithelial cells. Vacuolization is only modest in this instance. MT, original magnification  320. (j) Pseudocrescent in
collapsing glomerulopathy. Proliferating epithelial cells, with evident mitoses (arrows), fill much of Bowman’s space but do not obliterate it.
Note abundant hyaline droplets in the epithelial cells. MT, original magnification  550. (k) Tip lesion. Cellular lesion at tubular pole, with
foamy macrophage in lumen and adhesion to Bowman’s capsule. Remainder of the glomerulus shows only modest mesangial proliferation.
MT, original magnification  350. (l) Segmental scar with overlying epithelial prominence. The segmental scar is adherent to Bowman’s
capsule. The overlying epithelium is tall and often vacuolated (arrow). MT, original magnification  400.
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hyperplasia.’ As the diagnosis of primary FSGS is predicated
on the absence of diffuse glomerular immunoglobulin
deposition or of any other primary glomerular disease, it is
reasonable to attribute any segmental scars in that situation
to FSGS. In IgAN, however, there are diffuse glomerular IgA
deposits, mesangial hyperplasia, and focal glomerular ne-
croses (8.5% in our series) that may heal with segmental
scars, complicating the situation. A simple segmental scar,
although possibly representing FSGS, might also represent
healing of a segmental necrosis (Figure 2a and b). Therefore,
we required that such segmental scars have, in addition,
either overlying epithelial proliferation or hyalinosis lesions
in order to be diagnosed as FSGS NOS (Figure 2e–h and
Table 1).
A second adaptation of the Columbia classification was
that for the diagnosis of cellular FSGS in the context of IgAN,
we required the presence of hyperplastic epithelium overlying
the areas of endocapillary cellularity, to separate such lesions
from possible endocapillary hypercellularity of other causes
(Table 1).
The Oxford criteria define segmental glomerulosclerosis as
‘any amount of the tuft involved in sclerosis, but not
involving the whole tuft, or an adhesion’ (Figure 2). This
definition would include the simple segmental scars discussed
above, which were inadequate for diagnosis of FSGS in the
absence of added hyalinosis or epithelial proliferation. We
also took the conservative view that simple capsular
adhesions without evident lesions in the underlying tuft,
with (Figure 2d) or without (Figure 2c) accompanying
epithelial proliferation, although possibly representing early
FSGS, were inadequate to establish that diagnosis.
Classification of IgAN cases in terms of FSGS types. We
attempted to classify our cases of IgAN according to the 2004
pathologic classification of FSGS.14 For the most part, this
attempt worked well. It was possible to classify 103 of 128
(80.5%) cases among the 5 subtypes of FSGS (Table 3). Of
the remainder, 11 cases (8.6%) had glomerular lesions not
definably FSGS (7 with capsular adhesions only, 3 with
capsular adhesions with epithelial response, and 2 cases of
glomerular necroses, 1 having associated glomerular capsular
adhesions). Finally, there were 18 cases with no lesions on
light microscopy aside from mild mesangial prominence in
some. Common to all of the types of FSGS were capsular
adhesions that served as a bridge along which PECs grew
inward to cover the glomerular tuft (Figure 1g and h).
FSGS with classic hyalinosis lesions was found in 46
(35.1%) patients. The lesions were invariably adherent to
Bowman’s capsule. Interestingly, the majority of hyalinosis
lesions (37/46¼ 80.4%) were in nonhilar locations (Figure 1b).
Seg Glscl
Seg GlsclSeg Glscl
NOS NOS
NOSNOS
Figure 2 |Distinctions between segmental glomerulosclerosis
and focal segmental glomerulosclerosis, not otherwise
specified (FSGS, NOS). (a) Segmental necrosis and segmental
glomerulosclerosis. Lobule on left shows segmental necrotic
lesion, without significant overlying epithelial hyperplasia. On
right is a segmental scar adherent to the capsule with only
minimal epithelial prominence. Masson trichrome (MT), original
magnification  400. (b) Segmental glomerular scar. The scar,
without associated epithelial hyperplasia, is regarded as
representing simply segmental glomerulosclerosis, not FSGS. MT,
original magnification  400. (c) Capsular adhesion. This capsular
adhesion qualifies as segmental glomerulosclerosis under the
Oxford criteria, but has neither associated epithelial hyperplasia
nor lesions in the underlying lobule, and hence is not regarded
as FSGS under our definitions. MT, original magnification  550.
(d) Capsular adhesion with associated epithelial hyperplasia. This
lesion qualifies as segmental glomerulosclerosis under Oxford
criteria, but in the absence of lesions in the underlying tuft was
considered insufficient for diagnosis of FSGS. MT, original
magnification  475. (e) FSGS, NOS. There is a segmental scar,
upper left, with adherence to Bowman’s capsule and overlain by
reactive epithelium. Two capsular adhesions, one with epithelial
response, are seen at lower right (arrows). MT, original
magnification  400. (f) FSGS, NOS. In addition to segmental scars
with overlying epithelial prominence, there is a small hyalinosis
lesion (arrow) at top. MT, original magnification  300. (g) FSGS,
NOS. Segmental scar at lower left with extensive hyperplasia of
Bowman’s epithelium, and an additional adhesion (arrow) along
which epithelium, presumably of parietal epithelial cell (PEC)
origin, is growing. MT, original magnification  400. (h) FSGS,
NOS. Segmental scars with capsular adherence in one location,
with a small hyalinosis lesion (top arrow). The scarred areas are
overlain by hyperplastic and sometimes vacuolated epithelium.
Epithelial prominence is widespread (lower arrow). MT, original
magnification  350.
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These cases were subdivided into the Columbia classification
as follows: 7 cases the perihilar variant of FSGS, 9 cases the
cellular variant, with the remaining 30 cases relegated to the
FSGS, NOS category.
Collapsing glomerulopathy. Collapsing glomerulopathy
was found in 11 cases (Table 3). In its most distinctive form,
glomeruli were retracted with obliterated capillary lumens
surrounded by a halo of vacuolated cells, staining as
PECs28(Figure 1c and i). Partial involvement of glomeruli
was also seen with retracted lobules surrounded by a halo of
tall vacuolated, reactive PECs (Supplementary Figure S2
online). Capillary collapse and obliteration rather than
endocapillary proliferation is the primary feature distinguish-
ing this lesion from the cellular variant (see below). In fact, in
9/11 cases with collapsing glomerulopathy, other glomeruli
could be interpreted as the cellular variant, and 7/11 cases
had more typical lesions of FSGS with hyalinosis, emphasiz-
ing the spectrum of lesions seen in these cases. Of 11 cases, 8
had associated extracapillary proliferation, interpreted as
pseudocrescents (Figure 1j). All showed advanced parench-
ymal damage, with numerous vacuolated cells with the
morphology of macrophages in the tubular lumens, (Figure
1d). Clinically, they presented with advanced renal insuffi-
ciency and heavy proteinuria, with half having malignant
hypertension (Table 3). Of 10 patients with follow-up, 9
finished on hemodialysis, with the remaining patient having
an estimated GFR (eGFR) of 31ml/min per 1.73m2 at 22
months postbiopsy. (The eleventh patient was lost to follow-
up shortly after biopsy.)
Perihilar variant. The 7 perihilar variant cases, characterized
by hyalinosis lesions adjacent to the hilum, with or without
hyalinosis lesions elsewhere in the tuft, had substantial
proteinuria, and most were hypertensive, but had relatively
good outcomes (Table 3).
Tip lesions. These lesions consist of expansion of the
glomerular tuft at the tubular pole, the capillary lumens
being filled with cells, often foamy macrophages, the
overlying epithelium showing reactive changes and adhesions
to the capsule or initial proximal tubular basement
membrane (Figure 1k and Supplementary Figure S6 online).
We had six examples of tip lesions, four in pure form and two
associated with other lesions and classed as FSGS, NOS. The
four ‘pure’ cases had minimal parenchymal lesions and
modest proteinuria, but one nonetheless finished on dialysis
(Table 3). It should be pointed out that the relative frequency
of tip lesions in our series is lower than in primary FSGS,
with lower values for proteinuria, both observations remain-
ing unexplained for the present.
Cellular variant of FSGS. These lesions comprised lobules
with substantial endocapillary hypercellularity, often with
foam cells. As in primary FSGS, these hypercellular lobules
were almost always overlain by a prominent layer of
hyperplastic, often vacuolated PECs28 (Figure 1c and j).
Often it was possible to trace progression of these cells from
the capsule down onto and over the affected tuft (Figure 1g).
In all, 27 patients in our series had lesions diagnosable as
the cellular variant of FSGS (Table 3). In addition to the PECs
overlying the cellular lesions, 12 biopsies had extracapillary
Table 3 | Lesions of IgA nephropathy interpreted in terms of FSGS classification
Focal segmental glomerulosclerosis type
No lesions
Gl lesions,
not definably
FSGSa Tip lesion
Perihilar
hyalinosis FSGS, NOS
FSGS,
cellular
variant
Collapsing
glomerulopathy
16 patients 11 patients 4 patients 7 patients 52 patients 27 patients 11 patients
% Tubular atrophy/interstitial
fibrosis
5 (0–12.5) 15 (10–20) 10 (7.5–10) 30 (20–40) 20 (10–40) 40 (20–60) 70 (40–90)
Interstitial inflammation 0 (0–0) 1 (0–3) 0.5 (0–1.0) 2 (1–2) 1 (0–2) 2 (0–2) 1 (1–2)
Arteriosclerosis 1 (1–2) 1.5 (1–3) 1 (1–1.5) 3 (2–3) 2 (1–3) 2 (1–3) 2 (2–3)
Arteriolar lumen caliber 3 (2.5–3) 3 (2–3) 3 (3–3) 3 (2–3) 2.5 (2–3) 2 (2–3) 2 (1.5–2)
Thrombotic
microangiopathy
2/16=12.5% 2/11=18.2% 1/4=25% 6/7=85.7% 29/52=57.7% 19/27=70.4% 10/11=90.9%
Systolic BPdx 122 (113–135) 134 (120–156) 125 (119–140) 157 (136–180) 140 (127–161) 150 (130–170) 160 (130–197)
Diastolic BPdx 77 (68–89) 80 (63–93) 83 (74–93) 90 (80–110) 80 (70–97) 90 (80–102) 90 (70–120)
SCrdx 99 (84–113) 126 (97–161) 106 (101–108) 147 (91–190) 126 (89–193) 211 (158–498) 450 (298–1316)
eGFRdx 82 (65-87) 79 (50–91) 52 (51–71) 50 (34–68) 54 (37–76) 34 (13–44) 10.9 (4.3–20.9)
Proteinuriadx 0.28 (0.09–0.93) 1.70 (0.5–4.0) 0.97 (0.65–1.54) 1.60 (0.88–2.82) 1.45 (0.8–2.62) 2.63 (1.69–4.65) 3.99 (2.84–6.30)
Serum albumen 42.3 (36.5–47.3) 38.0 (34–41) 35.8 (32.6–39.0) 37.5 (36.5–41.5) 37.8 (35.0–40.0) 33.7 (28.7–39.1) 34.4 (31.0–38.8)
Hx. gross hematuria 7/13=53.8% 5/10=50% 1/3=33.3% 2/5=40% 14/43=32.6% 4/22=18.2% 0/11=0%
eGFRend
b 75 (61–100) 70 (50–91) 50 (22–64) 51 (34–61) 43 (7–67) 5 (5–32) 5 (5–5)
Bad outcomec 0/16=0% 1/10=10% 1/4=25% 1/7=14.3% 14/50=28% 14/24=58.3% 9/10=90%
Hemodialysis 0/16=0% 1/10=10% 1/4=25% 0/7=0% 11/50=22% 14/24=58.3% 9/10=90%
Abbreviations: BP, blood pressure; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; GI, glomerular; NOS, not otherwise specified;
SCr, serum creatinine.
Values expressed as mean±s.e.m. or as percentages. Probabilities calculated according to Mann–Whitney U-test or Fisher’s exact test, as appropriate.
Values in bold are significantly different from the group with no lesions, after correction by Holm–Bonferroni method to minimize type 1 statistical error (a=0.05).
aGlomerular lesions included: 7 cases with glomerular capsular adhesions only; 3 cases with capsular adhesions with epithelial response; and 2 cases with focal glomerular
necroses (1 having glomerular capsular adhesions as well).
bPatients on dialysis assigned an arbitrary eGFR=5ml/min per 1.73m2.
cBad outcome defined as doubling of SCr or need for dialysis.
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proliferative lesions, usually centered around the endocapil-
lary lesions (Supplementary Figure S8 online). Only one case
showed glomerular necroses. We also found that 12/27
(44.4%) had FSGS lesions with hyalinosis in other glomeruli.
Clinically, 24/27 (90.9%) presented with renal insufficiency,
all having substantial proteinuria (3.41±2.54 g per 24 h),
with 58% finishing on dialysis.
FSGS, NOS. There were 52 cases qualifying as FSGS, NOS.
In all, 11 cases had hyalinosis lesions, 23 cases segmental scars
with overlying epithelial proliferation (Figure 1l), or both (10
cases). Two cases had glomerular necroses, 2 tip lesions, and 5
some form of extracapillary proliferation. Clinically, protei-
nuria was only moderate, but nearly 80% were hypertensive
and 48% had renal insufficiency at presentation, with a
quarter finishing in terminal renal insufficiency.
Factors predictive of bad outcome
Renal survival at 80 months was 32.6% for patients with
FSGS versus 95.1% for those without (P¼ 0.00027; Figure 3).
Univariate analysis of the factors associated with bad
outcome is presented in Table 4. All of the expected clinical
factors (hypertension, proteinuria, SCr, and eGFR at
diagnosis) and parenchymal parameters (sclerotic glomeruli,
tubular atrophy, and interstitial fibrosis) were highly
associated with bad outcome. Morphologically, all three of
the glomerular parameters in the Oxford classification
(mesangial hypercellularity, endocapillary proliferation, and
segmental glomerulosclerosis) were associated with bad
outcome. Among FSGS types, collapsing glomerulopathy
and cellular variant were also associated with bad outcome.
Interrelationships between lesions of FSGS and Oxford criteria
parameters. All cases having lesions that we regarded as
representing FSGS, with the exception of 1 NOS and 2
cellular variant cases, qualified as having segmental glomer-
ulosclerosis under the Oxford criteria.15,16 Similarly, 39/41
examples of mesangial hypercellularity and 29/31 cases with
endocapillary proliferation occurred in the context of a form
of FSGS. However, it was possible to compare 42 cases in
which lesions of FSGS occurred alone with 47 cases in which
there was superimposed mesangial hypercellularity (15
cases), endocapillary proliferation (9 cases), or both (15
cases), as well as glomerular necroses (5 cases) and/or
extracapillary proliferation (22 cases). (Cases of collapsing
glomerulopathy were excluded, so as to not unduly weight
the analysis.) As might be expected, those with superimposed
glomerular lesions were worse for most morphologic,
clinical, and outcome parameters, although differences were
not significant after application of the Holm–Bonferroni
correction. Nevertheless, these differences, although not
individually significant, translated into worse survivals for
the group with superimposed lesions. By 80 months of
follow-up, renal survival of those with superimposed
glomerular lesions was 22.8 versus 49.2% for the ‘pure’ cases
(P¼ 0.0417; Figure 4).
However, the reverse point should be stressed as well. That
is, the cases with only FSGS had substantial morphologic
lesions, all had proteinuria, most were azotemic, and 25%
finished on hemodialysis The implication here is that FSGS
lesions, of themselves, are associated with substantial declines
in renal function and that the superimposed glomerular
lesions simply aggravate an already parlous situation.
Comparison of predictive power of Oxford criteria versus
FSGS. Table 5 compares analyses of the four Oxford criteria
and of the different types of FSGS in terms of their
association with Bad Outcome by Cox proportional hazards
modeling and the rate of decline of renal function by
multiple linear regression. (They cannot be compared
directly in a single analysis because of the extensive multi-
colinearity between the parameters in the two systems.)
Examination of the univariate analysis of clinical and
morphologic factors related to bad outcome (Table 4) reveals
the remarkable strength of the clinical prognostic factors,
notably hypertension, SCr, and the level of proteinuria at
diagnosis. The morphologic factors, although significant, are
not in the aggregate as strong as the clinical indicators,
whether analyzed according to the Oxford criteria or by
division according to FSGS type. These differences are
reflected in Cox multiple hazards modeling (Table 5), in
which eGFR sorts as significant in both models, but only
mesangial hyperplasia among the morphologic factors sorts
as significant. However, analysis of the rate of decline of renal
function by multiple linear regression does show endocapil-
lary proliferation and %tubular atrophy/interstitial fibrosis
among the Oxford criteria, and the NOS, cellular, and
collapsing variants among the FSGS types, to be significantly
associated with rate of decline.
DISCUSSION
Our study completely confirms the Oxford criteria15,16 in
another adult cohort, this one with somewhat more advanced
disease than in the Oxford study (Table 2). However, we feel
1.0
Survival from bad outcome
FSGS versus no FSGS
0.8
FSGS
No FSGS
P = 0.0011
0.6
Cu
m
u
la
tiv
e
 p
ro
po
rti
on
 s
ur
vi
vi
ng
0.4
0.2
0 20 40 60
Time (months)
80 100
Figure 3 | Survival from bad outcome—all cases. Kaplan–Meier
survival curves, comparing survival from bad outcome for all cases
with focal segmental glomerulosclerosis (FSGS) compared with
those without FSGS. Bad outcome is defined as doubling of serum
creatinine (SCr) or need for dialysis.
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that looking at IgAN in terms of variants of FSGS is a useful
alternative manner of looking at the disease. It raises new
questions regarding the pathogenesis of glomerular lesions in
IgAN. The evidence supporting this approach is as follows:
First, in this study we found 57 patients (44.5%) for whom
there can be no doubt as to their diagnosis as a form of FSGS:
46 patients with clearcut hyalinosis lesions and 11 patients
with collapsing glomerulopathy. An additional 44 patients
(34.3%) had lesions that we interpret as FSGS on the basis of
the criteria set forth in Table 1, for a total of nearly 80% of
patients showing some form of FSGS. This is a much higher
proportion of patients with FSGS than previously reported in
IgAN.10,11 Second, in another study28 we have shown
immunohistochemically that IgAN behaves basically identi-
cally to cases of primary FSGS, with progressive loss of
normal podocyte markers (synaptopodin, GLEPP-1 (glomer-
ular epithelial protein 1), nephrin, and vascular endothelial
growth factor) and marked increase in PECs, as indicated by
PAX2 and CK8, these latter proliferating inward along sites of
capsular adhesion onto the tuft to have an important role in
advanced lesions. Third is the presence of cytoplasmic
droplets positive for IgA in podocytes and PECs. Such
droplets are well recognized in collapsing glomerulopathy29,30
and in florid FSGS,31 but have not been previously described
in IgAN.
The question arises as to whether the FSGS is primary or
secondary to advancing renal parenchymal damage. Some
authors consider that FSGS is the final common pathway of
various pathophysiological mechanisms32,33 including the
FSGS in IgAN.34 Against this ‘final common pathway’
concept, however, we have shown that the lesions of FSGS
in IgAN may occur very early. Of the 101 patients with frank
FSGS, 31 had SCr p110 mmol/l and 28 had eGFR 460ml/
min per 1.73m2 at the time of biopsy, with correspondingly
mild parenchymal lesions (Figure 1k). These observations
argue against the idea that FSGS seen in IgAN might be due
simply to nephron reduction. Furthermore, we have demon-
strated loss of podocyte markers, such as GLEPP-1, in
glomeruli that are still morphologically normal.28 Thus, the
phenotypic changes in podocytes precede recognizable
glomerular lesions by light microscopy, suggesting that they
are the cause rather than the consequence of the latter.
Capsular adhesions are associated with scarring or active
lesions in the underlying tuft in many conditions. However,
in IgAN they frequently occur in the absence of recognizable
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Figure 4 | Survival from bad outcome—cases from Table 3.
Kaplan–Meier survival curves, comparing survival from bad
outcome for the cases included in Table 3. Cases with ‘pure’ focal
segmental glomerulosclerosis (FSGS) are compared with cases of
FSGS with superimposed other glomerular (GI) lesions (mesangial
hyperplasia, endocapillary hypercellularity, glomerular necroses,
and/or extracapillary proliferation). Bad outcome is defined as
doubling of serum creatinine (SCr) or need for dialysis.
Table 4 | Univariate analysis of factors associated with bad
outcome
Bad outcome
Preserved
renal function
Parameter 41 patients 80 patients P-value
Clinical parameters
Systolic BPdx 160 (140–180) 133 (121–150) 0.000002
Diastolic BPdx 90 (80–110) 80 (70–91) 0.0002
HTNdx 32/41=78.0% 30/80=37.5% 0.0000
Systolicend 135 (123–154) 124 (111–130) 0.000001
Malignant HTN 14/41=34.1% 3/80=3.75% 0.0000
Proteinuriadx 3.00 (1.73–5.50) 1.20 (0.50–2.47) 0.000004
Proteinuriaend 3.87 (2.26–5.01) 0.48 (0.10–1.07) 0.000001
Serum albumen 34.1 (29.5–38) 38.2 (35.2–42.0) 0.000004
SCrdx 371 (195–743) 107 (87–160) 0.000000
GFRdx 15.6 (8.4–34.1) 65.0 (44.2–83.8) 0.000000
TMA by laboratory
criteria
8/39=20.5% 0/80=0% 0.0001
Morphologic parameters
Oxford criteria
Mesangial hypercellularity 25/40=62.5% 16/80=20.0% 0.0000
Endocapillary proliferation 17/41=36.6% 14/80=17.5% 0.0093
Segmental
glomerulosclerosis
40/41=97.6% 1/80=1.3% 0.0000
Tubular atrophy/
interstitial fibrosis, %
60 (40–80) 15 (10–25) 0.000000
FSGS types
FSGS, any variant 40/41=97.6% 51/80=63.8% 0.0000
FSGS, NOS 14/41=34.1% 35/80=43.8% NS
FSGS, perihilar variant 1/41=2.4% 6/80=7.5% NS
FSGS, cellular variant 14/41=34.1% 11/80=13.8% 0.0087
FSGS, tip lesion 1/41=2.4% 3/80=3.8% NS
FSGS collapsing
glomerulopathy
10/41=24.4% 1/80=1.3% 0.0001
Other morphologic parameters
% Sclerotic glomeruli 71 (44–83) 16.7 (5.6–31.9) 0.000000
Extracapillary proliferation 17/40=42.5% 14/80=17.5% 0.0036
Glomerular necroses 0/41=0% 9/80=11.2% 0.027
Interstitial inflammation 2 (1–2) 0.5 (0–1) 0.000009
Microcystic change 14/38=36.8% 2/77=3.9% 0.0003
Arteriosclerosis 2 (2–3) 2 (1–2) 0.0044
TMA fibrinoid 23/41=56.1% 18/80=22.5% 0.0003
TMA organized 30/41=73.1% 28/80=35.0% 0.0001
Any TMA 35/40=85.4% 33/80=41.3% 0.0000
Abbreviations: BP, blood pressure; FSGS, focal segmental glomerulosclerosis; GFR,
glomerular filtration rate; HTN, hypertension; NOS, not otherwise specified; NS, not
significant; SCr, serum creatinine; TMA, thrombotic microangiopathy.
Values expressed as median (25–75th quartiles) or as percentages. Probabilities
calculated using Mann–Whitney U-test or Fisher’s exact test, as appropriate.
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underlying lesions, as is true in FSGS.28 Kriz18,19 refers to this
phenomenon as the ‘first committed step’ in the development
of FSGS. However, adhesions in the absence of underlying
lesions are rare in systemic lupus erythematosus, implying
that IgAN in this respect behaves more like FSGS than a
typical immune complex glomerulopathy.28
The causes of the podocyte lesion leading to FSGS are
undetermined for the moment. The possibility of toxicity,
either direct or indirect, of IgA1 on the podocyte is attractive.
It has been shown that serum IgA1 from patients with IgAN
leads to reduction of podocyte markers such as nephrin or
ezrin on podocytes in culture,22,35,36 as well as apoptosis of
podocytes.24 Furthermore, in children with IgAN, two types
of autophagy in podocytes have been observed, one (type II)
in which the ingested material is digested and disposed of in
normal fashion, the other (type I) in which the ingested
material persists undigested in the podocytes, and this type is
associated with more aggressive histological lesions.26 It is
tempting to attribute the accumulation of IgA in large
droplets in PECs and podocytes described above to this
phenomenon.
Role of FSGS in the progression of IgAN
Our study is the first to attempt to class lesions as FSGS
versus no FSGS and then to divide the FSGS group into the
different subclasses of FSGS as currently classified.27 We have
shown that cases with FSGS have a much worse renal survival
than do patients without FSGS (P¼ 0.00027; Figure 3). More
importantly, if one dissects the cases with FSGS into those
with ‘pure’ FSGS (excluding collapsing glomerulopathy) and
compares them with cases of FSGS with superimposed other
glomerular lesions (mesangial hyperplasia, endocapillary
hypercellularity, glomerular necroses, or extracapillary pro-
liferation), the cases of FSGS with superimposed other
glomerular lesions do worse that those with ‘pure’ FSGS, as
might be expected (Figure 4). But the differences are not
terribly great and the important observation is the reverse
one; that is, the cases with ‘pure’ lesions have a poor
prognosis, with 49.2% survival from bad outcome at 80
months. The different types of FSGS in our IgAN series had
outcomes broadly parallel to those in the literature for
primary FSGS,37–39 with collapsing glomerulopathy and the
cellular variant having a particularly poor prognosis.
Our findings suggest that lesions consistent with FSGS
should be sought systematically in evaluating cases with
IgAN, as an aid in thinking about prognosis and manage-
ment. This retrospective, observational study has the
limitation that although treatment was similar in the vast
majority of patients, there nonetheless remain differences
with unknown impact on prognosis.
Table 5 | Analysis of rate of decline of renal function and outcome
Oxford criteria model
Rate of decline of eGFR (ml/min per 1.73m2 per year) Factors associated with bad outcomea
Multiple linear regression F(7, 92)=6.1047,
Po0.00001, R2=0.3172
Cox proportional hazards modeling
w2=106.01, d.f.=7, P=0.00000
b s.e. b t-Value P-value b s.e. b t-Value P-value
Mesangial hyperplasia 0.0923 0.1053 0.8765 0.38 0.8404 0.3819 2.2054 0.027
Segmental glomerulosclerosis 0.1198 0.0953 1.2561 0.21 0.4012 0.5354 0.7495 0.45
Endocapillary proliferation 0.2124 0.1093 1.9435 0.055 0.0747 0.3644 0.2051 0.84
% Tubular atrophy/interstitial
fibrosis
0.5120 0.1351 3.7893 0.00026 0.0056 0.0106 0.5307 0.60
Proteinuriadx 0.1479 0.1112 1.3468 0.18 0.0352 0.0590 0.5961 0.55
eGFRdx 0.3586 0.1407 2.5481 0.012 0.0908 0.0220 4.1256 0.000037
Mean arterial pressuredx 0.0104 0.1097 0.0946 0.92 0.0069 0.0085 0.8117 0.42
FSGS model
Rate of decline of eGFR (ml/min per 1.73m2 per year) Factors associated with bad outcome
Multiple linear regression F(8, 103)=4.1988,
Po0.00022, R2=0.2459
Cox proportional hazards modeling
w2=105.36, d.f.=8, P=0.0000
b s.e. b t-Value P-value b s.e. b t-Value P-value
Collapsing glomerulopathy 0.3147 0.1066 2.9509 0.0039 1.2614 1.0893 1.1580 0.25
FSGS, NOS 0.3033 0.1134 2.6746 0.0087 0.5847 1.0391 0.5627 0.57
Perihilar variant 0.0570 0.0974 0.5851 0.56 0.5486 1.4390 0.3812 0.70
Cellular variant 0.4384 0.1171 3.743 0.0003 1.3599 1.0401 1.3075 0.19
Tip lesion 0.1167 0.0910 1.2793 0.20 1.6460 1.3860 1.1872 0.24
Proteinuriadx 0.2083 0.1044 1.9961 0.049 0.0153 0.0648 0.2367 0.81
eGFRdx 0.0896 0.1113 0.8042 0.42 0.0972 0.0173 0.9073 0.000000
Mean arterial pressuredx 0.0744 0.1035 0.7064 0.48 0.0046 0.0078 1.005 0.55
Abbreviations: eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; NOS, not otherwise specified.
aBad outcome defined as doubling of SCr or need for dialysis.
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Finally, we have been able to explain a great deal of the
progression of renal insufficiency in IgAN in terms of FSGS,
and have been able to categorize the majority of cases in
terms of the standard classes of FSGS. However, there remain
aspects of IgAN that are not explained in terms of FSGS.
Most notable is the near-universal presence of hematuria in
IgA patients. Microscopic hematuria is indeed seen in FSGS,
in roughly 30–60% of patients,40,41 but macroscopic hema-
turia is rare. Second is the presence of glomerular necroses in
IgAN.3 In FSGS, only in the cellular form are lesions
interpretable as segmental necroses seen, with cellular
infiltration and nuclear fragments.14 All of the glomerular
necroses in our series fit this definition. However, in other
series, frank fibrinoid necroses and cases with membrano-
proliferative appearance or widespread true crescents have all
been described,3 as well as IgA-dominant postinfectious
glomerulonephritis.42,43 Although all of these more florid
lesions are infrequent in IgAN, they indicate that thinking of
IgAN uniquely in terms of FSGS would be an oversimplifica-
tion. Although we are persuaded that FSGS accounts for
much of the progression of IgAN in patients considered
overall, these other lesions undeniably have a role as well.
Finally, although we feel that, using the criteria laid out in
Table 1, the basic diagnosis of FSGS in the context of IgAN
should be readily reproducible, division into the various
subtypes will be subject to considerable interobserver
variability, and will almost certainly not be as reliable as
the Oxford classification that was developed specifically and
rigorously with the aim of reproducibility.15,16
Conclusion
We have shown in this study that IgAN may be associated
with lesions of FSGS, similar to those of primary FSGS.
When present in ‘pure’ form they carry a moderately poor
prognosis, and when other glomerular lesions such as
mesangial hyperplasia or endocapillary hypercellularity are
superimposed the prognosis becomes yet worse. We suggest
that such lesions should be sought in the evaluation of
biopsies of IgAN for a better understanding of the
pathophysiology of the disease. However, we do not see
classification of lesions into FSGS types as a substitute for the
Oxford classification but rather as a complement to it,
offering different pathophysiological insights and perhaps in
the future leading to different therapies.
Conceiving of IgAN as a disease with a substantial
podocytic component serves to shift our thinking away from
the traditional view of IgAN as an intratuft lupus-like process
to a more global view in which all components of the
glomerulus are actively affected by the immune complexes.
PATIENTS AND METHODS
Patients
All adult (418 years) patients diagnosed with IgAN from
January 2002 to January 2008 in the Georges Pompidou
European Hospital Pathology Department were enrolled in this
retrospective study. These biopsies came from four different
medical centers. The diagnosis was based on the presence of
predominant IgA and C3 deposits in the mesangium. Patients
with systemic lupus erythematosus, Henoch–Scho¨nlein pur-
pura, chronic liver disease, or HIV infection were excluded, as
well as patients whose renal biopsy specimen contained o8
glomeruli, and those without sufficient initial clinical data,
leaving a total of 128 patients. Biopsies were performed for
isolated hematuria in four cases, and all others were biopsied
for some combination of hematuria, proteinuria, and/or
elevated SCr. Mean follow-up was 44±27 months. Among
the 121 patients with complete follow-up, 41 patients (34%)
met the criteria for bad outcome (doubling of SCr or need for
dialysis), with 36 patients (29.7%) requiring dialysis, 16 of
them within 3 months of diagnosis.
Clinical and laboratory data cited in this study included:
age, sex, blood pressure, number of antihypertensive agents
used, immunosuppressive therapy, proteinuria, hematuria,
and SCr. The GFR was estimated (eGFR) with the simplified
MDRD (Modification of Diet in Renal Disease) formula.44
These were collected at the time of renal biopsy, and at the
end of follow-up (or institution of renal replacement
therapy). The following definitions were used: hypertension:
systolic blood pressure 4140mmHg or diastolic blood
pressure 490mmHg or use of antihypertensive agents;
malignant hypertension: marked elevation of blood pressure,
associated with central nervous system symptoms (blurred
vision, headaches, nausea, vomiting, or papilledema). Bad
outcome was defined as doubling of SCr or renal replacement
therapy at the end of follow-up.
Renal histopathology
The renal biopsies were processed for light microscopy, and
direct immunofluorescence. Tissue for histology was fixed in
acetic acid–formol–absolute alcohol, and processed and stained
by standard methods. Sections (6mm) were stained for
immunofluorescence study with fluorescein isothiocyanate-
conjugated antibodies specific for human IgG, IgM, IgA, C1q,
C3, k and l light chains, and fibrin (DAKO, Carpinteria, CA).
All biopsy slides were re-reviewed by two senior pathologists
(DN and GH) without knowledge of clinical outcomes. The
biopsies were graded according to the Oxford classification of
IgAN.15,16 Glomerular lesions were also evaluated in terms of
possible lesions of FSGS using the proposed 2004 classification
of FSGS,14 as modified to apply to IgAN (Table 1). Thrombotic
microangiopathy lesions were described as: (1) ‘acute,’ with
fibrin deposits or (2) ‘organized,’ with evident fibrosis and
recanalization. The severity of interstitial cell infiltration,
interstitial fibrosis, and tubular atrophy was also semiquantita-
tively scored on a scale of 0–4þ ((0: none, 1: 0–25%, 2: 25–50%,
3: 50–75%, and 4: 475%). Arteries and arterioles were also
evaluated semiquantitatively (0–4þ ) for severity of arterio-
sclerosis and size of arteriolar lumen (with 3 taken as normal).
Statistical methods
Results were expressed as numerical values and percentages
for categorical variables. Continuous variables are expressed
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as median (25–75th percentile), because the majority had
non-Gaussian distribution. Comparisons were based on the
Fisher’s exact test for categorical data and the Student’s t-test
for normally distributed continuous data. For non-Gaussian
distributed parameters, we used the nonparametric Mann–
Whitney U-test to compare continuous variables, and the
Wilcoxon test to compare two paired groups.
The Oxford criteria and the FSGS variants were compared
in two fashions: rate of decline of eGFR was evaluated by
multiple linear regression. Cases reaching dialysis were
assigned an arbitrary residual eGFR of 5ml/min per
1.73m2. Outcome was evaluated by Cox proportional
hazards models, with Bad Outcome defined as doubling of
SCr or need for dialysis. Probability values of o0.05 were
regarded as statistically significant.
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